MiR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Zhou, Yong ^a   Huang, Zufa ^a   Wu, Song ^a   Zang, Xiaofang ^a   Liu, Min ^a   Shi, Jian ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Chemoresistance; microRNA; miR 33a; Osteosarcoma; TWIST

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 15B; MICRORNA 200A; MICRORNA 33A; MICRORNA 34C; MICRORNA 422A; MICRORNA 451; MICRORNA 611; MICRORNA 92A; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AGAR GEL ELECTROPHORESIS; AGE; APOPTOSIS; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RESTRICTION SITE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR NECROSIS; UPREGULATION;

3' UNTRANSLATED REGIONS; ADOLESCENT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NUCLEAR PROTEINS; OSTEOSARCOMA; RNA INTERFERENCE; TWIST TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84897971554     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-12     Document Type: Article

References (28)

1. The epidemiology of osteosarcoma. Ottaviani G, Jaffe N, Pediatric and Adolescent Osteosarcoma New York: Springer, Jaffe N, 2009 122 136
2. Phase 1 clinical trials for sarcomas: the cutting edge. Subbiah V, Kurzrock R, Curr Opin Oncol 2011 23 352 360 10.1097/CCO.0b013e3283477a94 21519259
3. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Chou AJ, Gorlick R, Expert Rev Anticancer Ther 2006 6 1075 1085 10.1586/14737140.6.7.1075 16831079
4. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Uribe-Botero G, Russell WO, Sutow WW, Martin RG, Am J Clin Pathol 1977 67 427 435 266360
5. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Geller DS, Gorlick R, Clin Adv Hematol Oncol 2010 8 705 718 21317869
6. Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Entz-Werlé N, Lavaux T, Metzger N, Stoetzel C, Lasthaus C, Marec P, Kalifa C, Brugieres L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Lutz P, Babin A, Oudet P, Gaub MP, Perrin-Schmitt F, Neoplasia 2007 9 678 688 10.1593/neo.07367 17786187
7. Dorso-ventral and rostro-caudal sequential expression of M-twist in the postimplantation murine embryo. Stoetzel C, Weber B, Bourgeois P, Bolcato-Bellemin AL, Perrin-Schmitt F, Mech Dev 1995 51 251 263 10.1016/0925-4773(95)00369-X 7547472
8. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, Bonaventure J, Nat Genet 1997 15 42 46 10.1038/ng0197-42 8988167
9. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Le Deley MC, Guinebretière J, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C, Brugières L, Vanel D, Dupoüy N, Tabone MD, Kalifa C, Eur J Cancer 2007 43 752 761 10.1016/j.ejca.2006.10.023 17267204
10. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Wu J, Liao Q, He H, Zhong D, Yin K, Mol Carcinog 2012 10.1002/mc.21991
11. TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Zhou Y, Zang X, Huang Z, Zhang C, Oncol Lett 2013 5 857 861 23426781
12. Circulating microRNAs in cancer: origin, function and application. Ma R, Jiang T, Kang X, J Exp Clin Cancer Res 2012 31 38 10.1186/1756-9966-31-38 22546315
13. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI, Cancer Res 2012 72 1865 1877 10.1158/0008-5472.CAN-11-2663 22350417
14. Regulation of microRNAs by epigenetics and their interplay involved in cancer. Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, Cao Y, J Exp Clin Cancer Res 2013 32 96 10.1186/1756-9966-32-96 24261995
15. MicroRNAs as therapeutic targets in cancer. Nana-Sinkam SP, Croce CM, Transl Res 2011 157 216 225 10.1016/j.trsl.2011.01.013 21420032
16. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R, Bacchini P, Donati D, Manfrini M, Bernini G, Lari S, Cancer 2003 97 3068 3075 10.1002/cncr.11456 12784343
17. Twist expression promotes migration and invasion in hepatocellular carcinoma. Matsuo N, Shiraha H, Fujik T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K, BMC Cancer 2009 9 240 10.1186/1471-2407-9-240 19615090
18. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Voorhoeve PM, Le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, Van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R, Cell 2006 124 1169 1181 10.1016/j.cell.2006.02.037 16564011
19. Analyzing real-time PCR data by the comparative C (T) method. Schmittgen TD, Livak KJ, Nat Protoc 2008 3 1101 1108 10.1038/nprot.2008.73 18546601
20. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J, Oncogene 2009 28 4065 4074 10.1038/onc.2009.274 19734943
21. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J, Mol Cancer 2010 9 96 10.1186/1476-4598-9-96 20433742
22. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B, PLoS One 2013 8 53906 10.1371/journal.pone.0053906 23372675
23. Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Yin K, Liao Q, He H, Zhong D, Med Oncol 2012 29 3449 3455 10.1007/s12032-012- 0317-6 22847601
24. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, Esplugues E, Fisher EA, Penalva LO, Moore KJ, Suárez Y, Lai EC, Fernández-Hernando C, Proc Natl Acad Sci USA 2011 108 9232 9237 10.1073/pnas.1102281108 21576456
25. The protooncogene Pim-1 is a target of miR-33a. Thomas M, Lange-Grunweller K, Weirauch U, Gutsch D, Aigner A, Grunweller A, Hartmann RK, Oncogene 2012 31 918 928 10.1038/onc.2011.278 21743487
26. miR-33-Mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, Gonzalez S, Cell Cycle 2010 9 3277 3285 20703086
27. Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. Kanamori M, Sano A, Yasuda T, Hori T, Suzuki K, J Exp Clin Cancer Res 2012 31 100 10.1186/1756-9966-31-100 23199169
28. Platinum compounds: a new class of potent antitumour agents. Rosenberg B, Vancamp L, Trosko JE, Mansour VH, Nature 1969 222 385 386 10.1038/222385a0 5782119